Captor Therapeutics Spolka Akcyjna

Warsaw Stock Exchange CTX.WA

Captor Therapeutics Spolka Akcyjna EBITDA for the year ending December 31, 2023: USD -16.42 M

Captor Therapeutics Spolka Akcyjna EBITDA is USD -16.42 M for the year ending December 31, 2023, a -154.98% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Captor Therapeutics Spolka Akcyjna EBITDA for the year ending December 31, 2022 was USD -6.44 M, a -6.67% change year over year.
Captor Therapeutics Spolka Akcyjna EBITDA for the year ending December 31, 2021 was USD -6.04 M, a -301.76% change year over year.
Captor Therapeutics Spolka Akcyjna EBITDA for the year ending December 31, 2020 was USD -1.50 M, a -67.11% change year over year.
Captor Therapeutics Spolka Akcyjna EBITDA for the year ending December 31, 2019 was USD -899.41 K, a -114.60% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

Warsaw Stock Exchange: CTX.WA

Captor Therapeutics Spolka Akcyjna

CEO	Dr. Thomas Shepherd Ph.D.
IPO Date	April 1, 2021
Location	Poland
Headquarters	ul. Dunska 11
Employees	105
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, focuses on the discovery and development of protein degradation drugs for cancer and autoimmune diseases. The company provides Targeted Protein Degradation technology that overcomes many existing drug limitations by removing proteins resistant to available therapeutics. It has five projects at the preclinical stage. The company was incorporated in 2015 and is based in Wroclaw, Poland.

Key trends

Past 5 years